Pfizer boss Ian Read flies in to put AstraZeneca takeover case to MPs
The pharmaceutical giant's chairman and chief executive, and his AstraZeneca counterpart, will appear before the Commons Business Committee this week
Sunday 11 May 2014
The chief executive of US pharmaceutical giant Pfizer will arrive in the UK tomorrow to persuade the Government that its £60bn-plus hostile takeover of British rival AstraZeneca should be allowed.
Concern has been raised that what would be the biggest ever corporate takeover in the UK could result in the loss of thousands of skilled jobs and damage British research. The Government can block such deals in exceptional circumstances if the public interest is at risk, although lawyers have said intervention in this case is unlikely to comply with European trade laws.
Pfizer's chairman and chief executive, Ian Read, and his AstraZeneca counterpart, Pascal Soriot, will appear before the Commons Business Committee on Tuesday and the Science and Technology Committee the next day. The science committee will also question Science Minister David Willetts.
While Pfizer has given assurances that it would keep at least 20 per cent of the combined companies' research and development workforce in the UK for at least five years and base its European headquarters in Britain, David Cameron has said he is "not satisfied".
Mr Read said in a video on the company website: "I see this as a win-win for society, a win-win for shareholders, and a win-win for stakeholders."
He also said the deal would "liberate the balance sheet and tax" of both companies.
The Chancellor George Osborne, said yesterday he would make sure Pfizer executives gave "real promises that we can hold them to".
"I'm also prepared to get in the room and have a hard negotiation with very large companies and be very, very hard-nosed about what we want to deliver in terms of good British science and good British jobs," he told Radio 4's Today programme.
Shadow Business Secretary, Chuka Umunna, has written to Business Secretary Vince Cable saying there is "wide concern … across the business and science communities about the deal". "The assurances Pfizer has given are not worth the paper they are written on, given that Pfizer has since refused to rule out breaking up AstraZeneca and selling off parts of it in the future," he said.
- 1 Finland schools: Subjects scrapped and replaced with 'topics' as country reforms its education system
- 2 The West has it totally wrong on Lee Kuan Yew
- 3 Watch: Man takes selfie every mile of 2,600 mile hike, creates amazing timelapse video
- 4 The day I starred in Only Fools and Horses
- 5 Scientists have discovered a simple way to cook rice that dramatically cuts the calories
Germanwings plane crash: Andreas Lubitz 'had eyesight problems' and woke from nightmares 'screaming we’re going down'
Saudi Arabia says it won't rule out building nuclear weapons
The battle for the Middle East's future begins in Yemen as Saudi Arabia jumps into the abyss
Jeremy Clarkson 'could be given minder' ahead of a potential Top Gear return
Zayn Malik's departure from One Direction shows the perils of fame in the age of social media
Ukip supporters are 55 or older, white and socially conservative, finds British Social Attitudes Report
JK Rowling responds to fan tweeting she 'can't see' Dumbledore being gay
Jeremy Clarkson sacked live: Alan Yentob 'wouldn't rule out' ex Top Gear host's BBC return
Revealed: Putin's army of pro-Kremlin bloggers
The West has it totally wrong on Lee Kuan Yew
Germanwings plane crash: Co-pilot Andreas Lubitz wanted to 'do something people would remember him for'
iJobs Money & Business
Negotiable: Recruitment Genius: To provide a prompt, friendly and efficient se...
Negotiable: Recruitment Genius: You will be the first point of contact for all...
£18000 - £24000 per annum + benefits: Ashdown Group: HR, Payroll & Benefits Of...
£35000 - £38000 per annum + benefits : Ashdown Group: A highly successful, int...